Roche's combination breast cancer treatment delivers positive results

Data from APHINITY study shows Roche’s Perjeta-based regimen reduces the risk of disease returning for people with HER2-positive early breast cancer - News - PharmaTimes

Related Keywords

Germany ,German ,Levi Garraway ,Institut Jules Bordet ,Breast International Group ,Frontier Science Foundation ,German Breast Group ,Sibylle Loibl , ,